What's Happening?
Ambry Genetics, a subsidiary of Tempus AI, has announced an enhancement to its Ambry CARE Program, which integrates breast density into the Tyrer-Cuzick breast cancer risk score within electronic health records (EHR). This update aims to provide clinicians with more precise and personalized risk estimates at the point of care, guiding recommendations for breast cancer screening and risk reduction. The Tyrer-Cuzick model, widely recommended by organizations such as the American College of Radiology, now includes breast density as a factor, improving the accuracy of risk assessments. This integration is designed to help identify patients who may benefit from advanced screening, such as annual breast MRI, particularly for those with a 20% or higher risk.
Why It's Important?
The integration of breast density into risk assessments is significant as it addresses a critical gap in breast cancer screening. Many women at elevated risk do not receive necessary screenings due to incomplete risk assessments. By embedding this information into EHRs, Ambry Genetics aims to streamline the process, making it easier for clinicians to access and act on risk data. This could lead to earlier detection and better outcomes for patients, potentially saving lives. The enhancement also aligns with FDA requirements for reporting breast density, ensuring compliance while improving patient care.
What's Next?
With the updated CARE Program, healthcare providers are expected to have improved tools for assessing breast cancer risk, potentially leading to increased screenings and preventive measures. As more clinicians adopt this technology, it could set a new standard for breast cancer risk assessment, influencing guidelines and practices across the healthcare industry. The success of this integration may also encourage further advancements in personalized medicine, leveraging digital tools to enhance patient care.
